HOME
SEARCH
RSS FEED
SUBSCRIBE
Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers
Case ID:
TAB-3683
Web Published:
12/6/2022
Description:
This invention relates to the stable and high-yield production of a high-potency toxin protein called DT390-EGF. This toxin was developed for the treatment of EGF-receptor-positive cancers, including bladder cancer. Initial methods for synthesizing DT390-EGF relied on the use of E. coli. However, the production in E. coli was difficult to prepare and had limited stability. Repeated efforts to standardize the process in E. coli gave poor yields, purity, and high variation.
To overcome the problems with production using E. coli, this invention employs the Pichia pastoris strain of yeast. To produce DT390-EGF in P. pastoris, the DNA encoding the DT390-EGF protein was modified to (a) introduce an N-terminal alanine, (b) optimize codon usage for efficient translation in P. pastoris, (c) abolish N-linked glycosylation sites, and (d) add a (G4S)3 linker between the DT390 and EGF moieties. With these changes, DT390-EFG can be reproducibly produced in P. pastoris with more stability and potency compared to that produced in E. coli.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech?title=Stable%2c_High-Yield_Productio n_of_DT390-EGF_Fusion_Protein_for_Treatment_of_EGF-Receptor-Positive_Cancers
Category(s):
Oncology
Therapeutics
Bookmark this page
Download as PDF
For Information, Contact:
Jennifer Wong
Technology Development Coordinator
NIH Technology Transfer
301-828-3707
jennifer.wong2@nih.gov
Inventors:
Jung-hee Woo
David Neville
Arthur Frankel
Andrew Thorburn
Michael Glode
Thomas Flaig
Keywords:
cancers
DT390-EGF
EGF
Fusion
POSITIVE
Protein
RECEPTOR
treatment
VCXXXX
WKXXXX
XEXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum